newsfilter
← Latest News
PR Newswire·

Oncopeptides enrolls the first patient in the phase 3 LIGHTHOUSE combination study in multiple myeloma

Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), today announced that the first patient has been dosed in the phase 3 LIGHTHOUSE study, evaluating...